'For
quarter ending March 2024, consolidated net sales (including other operating income) of Biocon has increased 3.79% to Rs 3917.1 crore compared to quarter ended March 2023. Sales of Generics segment has gone down 3.48% to Rs 718.40 crore (accounting for 17.99% of total sales). Sales of Biosimilars segment has gone up 12.19% to Rs 2,357.80 crore (accounting for 59.05% of total sales). Sales of Research service segment has gone down 7.79% to Rs 916.90 crore (accounting for 22.96% of total sales). Inter-segment sales came down from Rs 85.60 crore to Rs 76.00 crore. Profit before interest, tax and other unallocable items (PBIT) has slumped 37.43% to Rs 349.70 crore. PBIT of Generics segment fell 32.62% to Rs 50.40 crore (accounting for 14.41% of total PBIT). PBIT of Biosimilars segment fell 40.71% to Rs 90.30 crore (accounting for 25.82% of total PBIT). PBIT of Research service segment fel...
Pleaselogin & subscribe to view the full report.
More Reports
|
|